Bio-Rad Laboratories Inc. Class A Common Stock (BIO)

FairStock Score: 70/100 — STEADY

Key Financials

Strengths

• Generates $257 million in annual free cash flow (3.4% yield on market cap)
• Solid return on equity of 10.8% above cost of capital
• Conservative balance sheet with debt-to-equity of just 0.19, providing financial flexibility
• FairStock composite score of 70/100 places it in the top tier across value, quality, and momentum factors

AI Analysis

Bio-Rad Laboratories Inc. Class A Common Stock is a small-cap healthcare company valued at $7.5 billion. Revenue stands at $2.6 billion. From a quality standpoint, Bio-Rad shows Altman Z-Score of 2.9 in the grey zone and adequate 11% ROE. On valuation, the stock is attractively valued at 10.1x earnings, with offers a 33% margin of safety vs Graham Number of $416. Growth dynamics show revenue growing at 3.9% and profit growth of 200.6%. Our composite FairStock Score of 70/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $257 million in annual free cash flow (3.4% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer